ACR Convergence 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

NBCD A/S at ACR Convergence 2026

Nov 6–11, 2026 Orlando, FL ~15k attendees Website

NBCD A/S brings 3 presentations to ACR Convergence 2026 in Orlando. Its program centres on knee osteoarthritis pain, with clinical trial results for a fixed-dose combination of apocynin and paeonol and for LEVI-04, a neurotrophin modulator. It also looks at pain flares in a knee osteoarthritis trial.

OrganizationACR Convergence 2026 Attendance
NBCD A/S
Copenhagen, Denmark
Biotech companies
A biotechnology company developing drug candidates for osteoarthritis and pain.
Poster
Tue Nov 10
10:30am–12:30pm

Explore the full ACR Convergence 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Orlando. Leave your work email and we’ll be in touch.

Privacy

Download the full ACR Convergence 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at NBCD A/S

Tell us what you sell and we’ll find the people at NBCD A/S most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American College of Rheumatology (ACR). Organization details are derived from the ACR’s published program and exhibitor floor plan, and each organization’s own website. Submit a correction